|
Ipilimumab plus decitabine for patients with MDS or AML in posttransplant or transplant-naïve settings |
Apr 2023 |
Blood |
Myelodysplastic Syndromes (MDS) |
|
IPSS-M in myelodysplastic neoplasms arising from aplastic anemia and paroxysmal nocturnal hemoglobinuria |
Jun 2023 |
Blood |
Aplastic Anemia |
|
Iptacopan and danicopan for paroxysmal nocturnal hemoglobinuria |
Jun 2024 |
Journal of Managed Care & Specialty Pharmacy |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
|
Iptacopan for the treatment of paroxysmal nocturnal hemoglobinuria |
Oct 2024 |
Expert Opinion on Pharmacotherapy |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
|
Iptacopan for the treatment of paroxysmal nocturnal hemoglobinuria |
Oct 2024 |
Expert Opinion on Pharmacotherapy |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
|
Iron Chelation in Transfusion-Dependent Patients With Low- to Intermediate-1-Risk Myelodysplastic Syndromes |
Oct 2020 |
Annals of internal medicine |
Myelodysplastic Syndromes (MDS) |
|
Iron overload after complement inhibitor treatment of Paroxysmal Nocturnal Hemoglobinuria |
Apr 2021 |
American Journal of Hematology |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
|
Iron Overload Alters the Energy Metabolism in Patients With Myelodysplastic Syndromes: Results From the Multicenter FISM BIOFER Study |
Jun 2020 |
Scientific Reports |
Myelodysplastic Syndromes (MDS) |
|
Is blood transfusion safe during the COVID-19 pandemic? |
Sep 2020 |
Future Science OA |
Aplastic Anemia, Myelodysplastic Syndromes (MDS), Paroxysmal Nocturnal Hemoglobinuria (PNH) |
|
Is there a path forward for immunotherapy in patients with myelodysplastic syndromes? |
Jan 2024 |
Lancet Hematology |
Myelodysplastic Syndromes (MDS) |
